Yahoo · Sep 9, 2026
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
Tyra Biosciences and Johnson & Johnson are pursuing their own approaches to treating a common, early-stage form of bladder cancer.
NASDAQ · URGN
UroGen Pharma Ltd.
Healthcare · Biotechnology
$41.74
Up+$1.75 (+4.19%)
Updated Sep 16, 2026, 9:16 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.05B
- P/E ratio
- -6.89
- Dividend yield
- 0.00%
- 52-week range
- $15.86 – $50.81
- Volume
- 545.78K
- Avg. volume
- 1.14M
Price performance
URGN price history
1M range · 20 trading sessions · Daily adjusted prices
URGN closed at $41.74 after 20 trading sessions, down 14.68% for the selected period.
- Last close
- $41.74
- Period change
- -14.68%
- Period low
- $41.74
- Period high
- $50.29
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $43.25 | $43.25 | $41.09 | $41.74 | 545.78K |
| Sep 14, 2026 | $42.36 | $43.715 | $41.65 | $42.64 | 521.91K |
| Sep 11, 2026 | $43.13 | $43.61 | $41.60 | $42.31 | 687.46K |
| Sep 10, 2026 | $44.25 | $44.4799 | $41.85 | $42.24 | 688.67K |
| Sep 9, 2026 | $43.82 | $47.06 | $43.77 | $45.00 | 1.02M |
| Sep 8, 2026 | $43.24 | $44.7199 | $42.50 | $43.815 | 727.72K |
| Sep 4, 2026 | $44.54 | $45.095 | $43.50 | $44.09 | 779.04K |
| Sep 3, 2026 | $44.37 | $45.63 | $43.45 | $44.88 | 877.8K |
| Sep 2, 2026 | $44.01 | $45.88 | $43.49 | $44.42 | 473.5K |
| Sep 1, 2026 | $42.59 | $43.555 | $42.52 | $43.39 | 584.22K |
| Aug 31, 2026 | $43.17 | $44.86 | $42.00 | $43.09 | 749.05K |
| Aug 28, 2026 | $45.09 | $45.535 | $43.3898 | $43.62 | 580.05K |
| Aug 27, 2026 | $46.13 | $46.51 | $45.285 | $45.50 | 559.82K |
| Aug 26, 2026 | $46.00 | $46.6388 | $45.36 | $45.94 | 620.26K |
| Aug 25, 2026 | $46.65 | $47.17 | $45.67 | $46.36 | 570.16K |
| Aug 24, 2026 | $46.52 | $47.05 | $45.27 | $46.16 | 849.69K |
| Aug 21, 2026 | $47.13 | $47.28 | $45.60 | $46.86 | 755.58K |
| Aug 20, 2026 | $49.71 | $49.71 | $46.20 | $46.80 | 1.12M |
| Aug 19, 2026 | $49.89 | $50.81 | $48.55 | $50.29 | 2.39M |
| Aug 18, 2026 | $48.93 | $49.5599 | $48.41 | $48.92 | 823.74K |
Latest URGN news
The latest Smart Investors Daily articles mentioning URGN.
Stock researchCompany · Overview
URGN research
Overview
Company profile and research snapshot.
Company profile
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $23.50
- Implied upside
- —
- Analysts
- 14
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | Guggenheim | Buy | — |
| Aug 6, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 5, 2026 | TD Cowen | Buy | — |
| Jul 21, 2026 | Guggenheim | Buy | — |
| Jul 16, 2026 | Oppenheimer | Outperformer | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Sep 9, 2026
Urogen Pharma: Upside After Bladder Cancer Launch
Buy UroGen Pharma Ltd.: Zusduri adoption and strong ENVISION results, plus URGN-103 NDA progress, support upside despite cash runway risks. Click for a URGN update.
ChartMill · Sep 5, 2026
UroGen Pharma (NASDAQ:URGN) Combines High Growth Momentum with a Breakout Setup
UroGen Pharma (URGN) shows accelerating revenue and a strong technical setup, rated 6 for High Growth Momentum. A compelling crossover to watch.
Yahoo · Sep 4, 2026
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 19 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution and ZUSDURI™ (mitomycin) f
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
